PR antagonism of 1 and analogues was assessed in T-47D breast cancer cells by measuring their effect in the presence of ORG2058, a highly active synthetic PR agonist that induces well-documented transcriptional targets including the FKBP54 and S100P genes30–33. The gene discussed is FKBP5; the disease is breast cancer.